
David A Watkins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/642036/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Community Perspectives on Primary Prevention of Rheumatic Heart Disease in Uganda. Global Heart, 2022, 17, 5.	0.9	6
2	Health trends, inequalities and opportunities in South Africa's provinces, 1990–2019: findings from the Global Burden of Disease 2019 Study. Journal of Epidemiology and Community Health, 2022, 76, 471-481.	2.0	21
3	Mortality Along the Rheumatic Heart Disease Cascade of Care in Uganda. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, e008445.	0.9	3
4	Understanding the local and international stakeholders in rheumatic heart disease field in Tanzania and Uganda: A systematic stakeholder mapping. International Journal of Cardiology, 2022, 353, 119-126.	0.8	1
5	A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases. Clinical Infectious Diseases, 2022, 75, 1245-1254.	2.9	5
6	A tool to identify NCD interventions to achieve the SDG target. The Lancet Global Health, 2022, 10, e949-e950.	2.9	1
7	Modeling global 80-80-80 blood pressure targets and cardiovascular outcomes. Nature Medicine, 2022, 28, 1693-1699.	15.2	26
8	Economic consequences of rheumatic heart disease: A scoping review. International Journal of Cardiology, 2021, 323, 235-241.	0.8	13
9	Epidemiology, Risk Factors, Burden and Cost of Acute Rheumatic Fever and Rheumatic Heart Disease. , 2021, , 1-18.		6
10	Examining the Ugandan health system's readiness to deliver rheumatic heart disease-related services. PLoS Neglected Tropical Diseases, 2021, 15, e0009164.	1.3	10
11	A global compact to counter vaccine nationalism. Lancet, The, 2021, 397, 2046-2047.	6.3	6
12	Achieving global mortality reduction targets and universal health coverage: The impact of COVID-19. PLoS Medicine, 2021, 18, e1003675.	3.9	8
13	An investment case for the prevention and management of rheumatic heart disease in the African Union 2021–30: a modelling study. The Lancet Global Health, 2021, 9, e957-e966.	2.9	40
14	Household Economic Consequences of Rheumatic Heart Disease in Uganda. Frontiers in Cardiovascular Medicine, 2021, 8, 636280.	1.1	9
15	Health system costs of rheumatic heart disease care in South Africa. BMC Public Health, 2021, 21, 1303.	1.2	7
16	Prioritizing Health-Sector Interventions for Noncommunicable Diseases and Injuries in Low- and Lower-Middle Income Countries: National NCDI Poverty Commissions. Global Health, Science and Practice, 2021, 9, 626-639.	0.6	10
17	Incidence of acute rheumatic fever in northern and western Uganda: a prospective, population-based study. The Lancet Global Health, 2021, 9, e1423-e1430.	2.9	16

Balancing health and financial protection in health benefit package design. Health Economics (United) Tj ETQq0 0 0 orgBT /Overlock 10 T

DAVID A WATKINS

#	Article	IF	CITATIONS
19	Universal health coverage must become a best buy for women. Lancet, The, 2021, 398, 2215-2217.	6.3	2
20	The Health Systems Barriers and Facilitators for RHD Prevalence: An Epidemiological Meta-Analysis From Uganda and Tanzania. Global Heart, 2020, 12, 5.	0.9	15
21	The American Heart Association's Call to Action for Reducing the Global Burden of Rheumatic Heart Disease: A Policy Statement From the American Heart Association. Circulation, 2020, 142, e358-e368.	1.6	30
22	Protecting essential health services in low-income and middle-income countries and humanitarian settings while responding to the COVID-19 pandemic. BMJ Global Health, 2020, 5, e003675.	2.0	47
23	The Lancet NCDI Poverty Commission: bridging a gap in universal health coverage for the poorest billion. Lancet, The, 2020, 396, 991-1044.	6.3	165
24	Active Case Finding for Rheumatic Fever in an Endemic Country. Journal of the American Heart Association, 2020, 9, e016053.	1.6	12
25	Cardiovascular health and COVID-19: time to reinvent our systems and rethink our research priorities. Heart, 2020, 106, 1870-1872.	1.2	5
26	Resource requirements for essential universal health coverage: a modelling study based on findings from Disease Control Priorities, 3rd edition. The Lancet Global Health, 2020, 8, e829-e839.	2.9	29
27	Health-care investments for the urban populations, Bangladesh and India. Bulletin of the World Health Organization, 2020, 98, 19-29.	1.5	7
28	Integrating the Prevention and Control of Rheumatic Heart Disease into Country Health Systems: A Systematic Review and Meta-Analysis. Global Heart, 2020, 15, 62.	0.9	7
29	Proactive prevention: Act now to disrupt the impending non-communicable disease crisis in low-burden populations. PLoS ONE, 2020, 15, e0243004.	1.1	1
30	Community study to uncover the full spectrum of rheumatic heart disease in Uganda. Heart, 2019, 105, 60-66.	1.2	22
31	Trends and presentation patterns of acute rheumatic fever hospitalisations in the United States. Cardiology in the Young, 2019, 29, 1387-1390.	0.4	11
32	Integrating the prevention and control of rheumatic heart disease into country health systems: a systematic review protocol. BMJ Open, 2019, 9, e028908.	0.8	1
33	Making cardiac surgery feasible in African countries: Experience from Namibia, Uganda, and Zambia. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 1384-1393.	0.4	26
34	Investing in non-communicable disease risk factor control among adolescents worldwide: a modelling study. BMJ Global Health, 2019, 4, e001335.	2.0	16
35	Policy options for tackling diet-related noncommunicable diseases. Bulletin of the World Health Organization, 2019, 97, 442-442A.	1.5	4
36	Task sharing to improve the prevention, diagnosis and management of rheumatic heart disease: a systematic review protocol. BMJ Open, 2018, 8, e019511.	0.8	3

DAVID A WATKINS

#	Article	IF	CITATIONS
37	Global Burden of Rheumatic Heart Disease. New England Journal of Medicine, 2018, 378, e2.	13.9	15
38	Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition. Lancet, The, 2018, 391, 1224-1236.	6.3	101
39	Costs and cost-effectiveness of HIV/noncommunicable disease integration in Africa. Aids, 2018, 32, S83-S92.	1.0	32
40	Alma-Ata at 40 years: reflections from the Lancet Commission on Investing in Health. Lancet, The, 2018, 392, 1434-1460.	6.3	71
41	Rheumatic Heart Disease Worldwide. Journal of the American College of Cardiology, 2018, 72, 1397-1416.	1.2	137
42	Implications of the 2017 ACC/AHA Hypertension Guideline for Public Health in Nepal. JAMA Network Open, 2018, 1, e180778.	2.8	9
43	Universal health coverage and intersectoral action for health: key messages from Disease Control Priorities, 3rd edition. Lancet, The, 2018, 391, 1108-1120.	6.3	153
44	Setting priorities to address cardiovascular diseases through universal health coverage in low- and middle-income countries. Heart Asia, 2017, 9, 54-58.	1.1	5
45	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. Journal of the American College of Cardiology, 2017, 70, 1-25.	1.2	2,705
46	Group A Streptococcus, Acute Rheumatic Fever and Rheumatic Heart Disease: Epidemiology and Clinical Considerations. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 15.	0.4	97
47	Rheumatic heart disease across the Western Pacific: not just a Pacific Island problem. Heart Asia, 2017, 9, e010948.	1.1	7
48	Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. New England Journal of Medicine, 2017, 377, 713-722.	13.9	771
49	Ranking 93 health interventions for low- and middle-income countries by cost-effectiveness. PLoS ONE, 2017, 12, e0182951.	1.1	69
50	Moving Forward the RHD Agenda at Global and National Levels. Global Heart, 2017, 12, 1.	0.9	5
51	The WHF Roadmap for Reducing CV Morbidity and Mortality Through Prevention and Control of RHD. Global Heart, 2017, 12, 47.	0.9	44
52	A Comprehensive Needs Assessment Tool for Planning RHD Control Programs in Limited Resource Settings. Global Heart, 2017, 12, 25.	0.9	13
53	Structural Heart Diseases. , 2017, , 191-208.		4
54	Relationships among Major Risk Factors and the Burden of Cardiovascular Diseases, Diabetes, and		4

Chronic Lung Disease. , 2017, , 23-36.

#	Article	IF	CITATIONS
55	Universal Health Coverage and Intersectoral Action for Health. , 2017, , 1-21.		1
56	Palliative Care and Pain Control. , 2017, , 235-246.		5
57	Intersectoral Policy Priorities for Health. , 2017, , 23-41.		7
58	Universal Health Coverage and Essential Packages of Care. , 2017, , 43-65.		35
59	Interventions to Prevent Injuries and Reduce Environmental and Occupational Hazards: A Review of Economic Evaluations from Low- and Middle-Income Countries. , 2017, , 199-211.		3
60	Injury Prevention and Environmental Health: Key Messages from Disease Control Priorities, Third Edition. , 2017, , 1-23.		3
61	Trends in Morbidity and Mortality Attributable to Injuries and Selected Environmental Hazards. , 2017, , 25-34.		4
62	Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies. , 2017, , 369-374.		3
63	Cardiovascular, Respiratory, and Related Disorders: Key Messages and Essential Interventions to Address Their Burden in Low- and Middle-Income Countries. , 2017, , 1-21.		7
64	Epidemiology, health systems and stakeholders in rheumatic heart disease in Africa: a systematic review protocol. BMJ Open, 2016, 6, e011266.	0.8	12
65	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	6.3	413
66	Delivery of health care for cardiovascular and metabolic diseases among people living with HIV/AIDS in African countries: a systematic review protocol. Systematic Reviews, 2016, 5, 63.	2.5	8
67	Cardiovascular disease and impoverishment averted due to a salt reduction policy in South Africa: an extended cost-effectiveness analysis. Health Policy and Planning, 2016, 31, 75-82.	1.0	38
68	A Cost-Effectiveness Tool to Guide the Prioritization of Interventions for Rheumatic Fever and Rheumatic Heart Disease Control in African Nations. PLoS Neglected Tropical Diseases, 2016, 10, e0004860.	1.3	21
69	Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiqué. Cardiovascular Journal of Africa, 2016, 27, 184-1847.	0.2	104
70	Global Noncommunicable Disease Research: Opportunities and Challenges. Annals of Internal Medicine, 2015, 163, 712-714.	2.0	13
71	Provider costs for prevention and treatment of cardiovascular and related conditions in low- and middle-income countries: a systematic review. BMC Public Health, 2015, 15, 1183.	1.2	54
72	Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. The Lancet Global Health, 2015, 3, e288-e296.	2.9	85

DAVID A WATKINS

#	Article	IF	CITATIONS
73	Limb-girdle weakness in a marfanoid man: distinguishing calpainopathy from Becker's muscular dystrophy. Practical Neurology, 2015, 15, 152-154.	0.5	2
74	Incidence, prevalence and outcome of rheumatic heart disease in South Africa: A systematic review of contemporary studies. International Journal of Cardiology, 2015, 199, 375-383.	0.8	42
75	A Cost-Effectiveness Analysis of a Program to Control Rheumatic Fever and Rheumatic Heart Disease in Pinar del Rio, Cuba. PLoS ONE, 2015, 10, e0121363.	1.1	33
76	Incidence, prevalence and outcomes of rheumatic heart disease in South Africa: a systematic review protocol. BMJ Open, 2014, 4, e004844-e004844.	0.8	14
77	The burden of antenatal heart disease in South Africa: a systematic review. BMC Cardiovascular Disorders, 2012, 12, 23.	0.7	50
78	Benzathine Penicillin for Recurrence of Rheumatic Fever: The Jury Is Still Out. Pediatric Cardiology, 2011, 32, 247-247.	0.6	1
79	Individual Genomes on the Horizon. New England Journal of Medicine, 2010, 363, 195-196.	13.9	0
80	Lessons from the first report of the Arrhythmogenic Right Ventricular Cardiomyopathy Registry of South Africa. Cardiovascular Journal of Africa, 2010, 21, 129-130.	0.2	5
81	Rheumatic Fever: Neglected Again. Science, 2009, 324, 37-37.	6.0	32
82	Clinical features, survival experience, and profile of plakophylin-2 gene mutations in participants of the Arrhythmogenic Right Ventricular Cardiomyopathy Registry of South Africa. Heart Rhythm, 2009, 6, S10-S17.	0.3	51